Loading stock data…
Bristol-Myers Squibb Company discovers (BMY)
$58.12+0.60 (+1.03%)
Market OpenUpdated 3:15 PM EDT
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bristol-Myers Squibb Company in the Healthcare sector is trading at $58.12 with a market capitalization of $114.6B. Wall Street consensus targets $63.08 (25 analysts), implying a +8.5% move over the next 12 months. The stock is currently 8% below its 52-week high of $62.89, remaining 9.2% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +8.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.49B↓ | $12.50B↑ | $12.22B↓ | $12.27B↑ | $11.20B |
| Gross Profit | $8.07B↓ | $8.41B↓ | $8.79B↓ | $8.90B↑ | $8.17B |
| Operating Income | $3.37B↑ | $2.81B↓ | $3.64B↓ | $3.77B↑ | $3.50B |
| Net Income | $2.68B↑ | $1.09B↓ | $2.20B↑ | $1.31B↓ | $2.46B |
Peer Comparison
JNJUNHPFE
Fundamentals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. Th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$114.59B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
4.30%
ROE
Elite ROE. Management converts capital into profit efficiently.
36.25%
Volume
Today's trading volume
5.19M
Recent News
AbbVie Stock Rockets 17% With 5-Day Winning Streak
AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.
66 With $1.3 Million. Here Are 3 Hidden Gems to Target
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb: ... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target
AbbVie Stock's Growth Story Has One Question Mark
The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.